Inventor
WU TONGFEI
BE29 patents
⚠️ This page may combine multiple inventors who share the name “WU TONGFEI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN PHARMACEUTICA NV
15 patentsUS11059850B2Jul 13, 2021
Spirobicyclic analogues
JANSSEN PHARMACEUTICA NV8 citations81
US10653711B2May 19, 2020
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV6 citations81
US10888550B2Jan 12, 2021
Pyrazole derivatives as MALT1 inhibitors
JANSSEN PHARMACEUTICA NV3 citations71
US11702441B2Jul 18, 2023
Spirobicyclic analogues
JANSSEN PHARMACEUTICA NV2 citations70
US11318157B2May 3, 2022
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV1 citations70
US10954214B2Mar 23, 2021
Pyrazole derivatives as MALT1 inhibitors
JANSSEN PHARMACEUTICA NV5 citations69
US11883367B2Jan 30, 2024
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations60
US11040031B2Jun 22, 2021
Pyrazole derivatives as MALT1 inhibitors
JANSSEN PHARMACEUTICA NV2 citations60
US12145961B2Nov 19, 2024
Spirobicyclic analogues
JANSSEN PHARMACEUTICA NV0 citations59
US12077521B2Sep 3, 2024
Pyrazole derivatives as MALT1 inhibitors
JANSSEN PHARMACEUTICA NV0 citations59
US11993614B2May 28, 2024
Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations59
US11098062B2Aug 24, 2021
Monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations59
US12404260B2Sep 2, 2025
Pyridine rings containing derivatives as MALT1 inhibitors
JANSSEN PHARMACEUTICA NV0 citations47
US10898504B2Jan 26, 2021
Substituted nucleoside analogues for use as PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations47
US11571437B2Feb 7, 2023
Methods of treating cancer using PRMT5 inhibitors
JANSSEN PHARMACEUTICA NV0 citations39
ALIGOS THERAPEUTICS INC
5 patentsUS12018015B2Jun 25, 2024
Methods and compositions for targeting PD-L1
ALIGOS THERAPEUTICS INC2 citations71
US12534450B2Jan 27, 2026
Methods and compositions for targeting PD-L1
ALIGOS THERAPEUTICS INC0 citations61
US11760761B2Sep 19, 2023
Methods and compositions for targeting PD-L1
ALIGOS THERAPEUTICS INC2 citations61
US11760764B2Sep 19, 2023
Methods and compositions for targeting PD-L1
ALIGOS THERAPEUTICS INC2 citations61
US12428427B2Sep 30, 2025
Methods and compositions for targeting PD-L1
ALIGOS THERAPEUTICS INC0 citations50
LEUVEN K U RES & DEV
3 patentsUS9249177B2Feb 2, 2016
Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
LEUVEN K U RES & DEV2 citations61
US8809520B2Aug 19, 2014
Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
LEUVEN K U RES & DEV3 citations61
US9522932B2Dec 20, 2016
Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
LEUVEN K U RES & DEV0 citations51
HERDEWIJN PIET
2 patentsUS8076310B2Dec 13, 2011
Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
HERDEWIJN PIET14 citations87
US8501709B2Aug 6, 2013
Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
HERDEWIJN PIET3 citations60